EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling

Qi Chen, Yupei Zhang, Shiyang Wang, Ruxuan Chen, Yujie Shi, Zhiyi Li, Chi Shao, Shaoyan Gao, Honggang Zhou, Hui Huang iD

Lung · 2026

DOI: 10.1007/s00408-026-00936-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung, 2026. Verfasst von Qi Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medic…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Interleukin-4 Receptor alpha Subunit, Idiopathic Pulmonary Fibrosis, Macrophages. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) of unclear etiology. Dupilumab, a humanized monoclonal antibody binding to interleukin-4 receptor alpha (IL-4Rα), suppresses both IL-4 and IL-13 signaling pathways. However, the therapeutic potential in IPF is unclear. This research aimed to evaluate the antifibrotic efficacy of dupilumab and illustrate the underlying mechanisms.

Methods

The antifibrotic efficacy of dupilumab was assessed both in vitro and in vivo. In vitro, a fibroblast activation model and a macrophage-fibroblast co-culture model were established. In vivo, pulmonary fibrosis was induced in C57BL/6 mice by intratracheal bleomycin injection. Lung function, micro-computed tomography (micro-CT), histopathology, inflammatory responses, and fibrosis-related signaling pathways were assessed.

Results

Dupilumab significantly suppressed TGF-β1-induced fibroblast activation. In the macrophage-fibroblast coculture system, dupilumab inhibited the profibrotic phenotype of IL-4/IL-13-stimulated macrophages, as well as macrophage-induced myofibroblast activation. In bleomycin-challenged mice, dupilumab improved pulmonary function, alleviated radiographic and histopathological fibrosis, reduced inflammatory cell counts and inflammatory cytokine levels in bronchoalveolar lavage fluid. Mechanistically, dupilumab suppressed activation of both the TGF-β1/Smad and JAK/STAT pathways in fibrotic lung tissues.

Conclusions

Dupilumab attenuates pulmonary fibrosis by disrupting profibrotic macrophage-fibroblast crosstalk and suppressing fibroblast activation. In preclinical models, dupilumab mitigated BLM-induced pulmonary inflammation and early-stage fibrosis in mice and inhibited the TGF-β1-Smad and JAK-STAT signal transduction cascades. These findings identify IL-4Rα-mediated signaling as a promising intervention point in pulmonary fibrosis and support further investigation of dupilumab as a candidate therapy for fibrotic lung diseases. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedInterleukin-4 Receptor alpha SubunitIdiopathic Pulmonary FibrosisMacrophagesFibroblastsAntifibrotic AgentsAnimalsSignal TransductionMice, Inbred C57BLBleomycinCoculture TechniquesDisease Models, AnimalSTAT Transcription FactorsJanus KinasesInterleukin-13Interleukin-4LungMaleReceptors, Interleukin-4HumansTransforming Growth Factor beta1Mice

Stichwörter der Autor:innen

DupilumabFibroblastsIdiopathic pulmonary fibrosisInterleukin-4 receptorMyofibroblast activationProfibrotic macrophages

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-4 Receptor alpha SubunitBleomycindupilumabIl4ra protein, mouseSTAT Transcription FactorsJanus KinasesInterleukin-13Interleukin-4Receptors, Interleukin-4

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China. ShaoyanGao339@163.com.
  • State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China. honggang.zhou@nankai.edu.cn.
  • Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. pumchhh@126.com.

ORCID-Profile: Hui Huang

Zitieren

APA

Chen, Q., Zhang, Y., Wang, S., Chen, R., Shi, Y., Li, Z., Shao, C., Gao, S., Zhou, H., & Huang, H. (2026). Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling. Lung. https://doi.org/10.1007/s00408-026-00936-5

Vancouver

Chen Q, Zhang Y, Wang S, Chen R, Shi Y, Li Z, et al. Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling. Lung. 2026. doi:10.1007/s00408-026-00936-5

BibTeX
@article{Chen2026,
  author = {Chen, Qi and Zhang, Yupei and Wang, Shiyang and Chen, Ruxuan and Shi, Yujie and Li, Zhiyi and Shao, Chi and Gao, Shaoyan and Zhou, Honggang and Huang, Hui},
  title = {Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling},
  journal = {Lung},
  year = {2026},
  doi = {10.1007/s00408-026-00936-5}
}
Kostenlos starten →